News | Breast Imaging | March 07, 2019

Hologic Earns CE Mark for LOCalizer Wireless Breast Lesion Localization System

Latest addition to growing portfolio of breast and skeletal health innovations to be featured at ECR 2019

Hologic Earns CE Mark for LOCalizer Wireless Breast Lesion Localization System

March 7, 2019 — Hologic Inc. announced the granting of a CE Mark to the LOCalizer wireless radio frequency identification (RFID) breast lesion localization system. This system is designed for precise and easy marking and targeting of lesions for breast-conserving surgery guidance.

The system is one of many in Hologic’s expanding suite of breast and skeletal health products, including screening, interventional, ultrasound and surgical solutions, that was available for demonstration at the annual European Congress of Radiology (ECR) meeting, Feb. 27-March 3 in Vienna, Austria.

The LOCalizer tag is designed to replace the traditional wire-guided localization method, helping to provide increased comfort and convenience for patients and their healthcare teams. The tag can be implanted up to 30 days prior to a breast-conserving surgery, providing increased flexibility for patients and providers. This improved workflow is designed to help reduce scheduling and logistical hurdles for care teams, and aims to deliver added convenience for an enhanced patient experience. Following placement, the miniature implantable tag can be detected by a portable, handheld reader that indicates the location and distance in millimeters to the lesion, enabling the surgeon to pinpoint the correct area of breast tissue for removal.

Along with the LOCalizer system, Hologic’s newest products in the breast health market include:

  • The SmartCurve breast stabilization system;
  • Clarity HD high-resolution 3-D imaging technology;
  • The Viera portable breast ultrasound system; and
  • The Brevera breast biopsy system with CorLumina imaging technology, which features real-time imaging and sample verification.

Two recent acquisitions of digital specimen radiography company Faxitron Bioptics and Focal Therapeutics, manufacturer of the BioZorb marker, have enabled Hologic to play a larger role in breast-conserving surgery.

Visitors to the Hologic booth at ECR experienced the A.I. Future Suite, where they had a chance to experience current and future applications of artificial intelligence (AI) in breast imaging. In addition, the company’s entire suite of breast and skeletal health products, such as the 3Dimensions Mammography System and Fluoroscan Insight FD Mini C-Arm, were on display and available for demonstration.

Hologic also hosted a variety of workshops during ECR 2019 and a symposium, Advances in Breast Imaging: Clinical use of CEDM across Europe. Workshop topics offered hands-on experience and expert insight into topics including: clinical workflow using tomosynthesis guidance and real-time breast biopsy imaging; a new technique for breast lesion localization; wireless ultrasound guided biopsies; contrast-enhanced mammography in clinical practice; optimization of tomosynthesis reading time; and breast density case reviews.

For more information: www.hologic.com

Related Content

iCAD's ProFound AI Wins Best New Radiology Solution in 2019 MedTech Breakthrough Awards
News | Computer-Aided Detection Software | September 09, 2019
iCAD Inc. announced MedTech Breakthrough, an independent organization that recognizes the top companies and solutions...
A smart algorithm has been trained on a neural network to recognize the appearance of breast cancer in MR images

A smart algorithm has been trained on a neural network to recognize the appearance of breast cancer in MR images. The algorithm, described at the SBI/ACR Breast Imaging Symposium, used deep learning, a form of machine learning, which is a type of artificial intelligence. Image courtesy of Sarah Eskreis-Winkler, M.D.

Feature | Society of Breast Imaging (SBI) | September 06, 2019 | By Greg Freiherr
The use of smart algorithms has the potential to make healthcare more efficient.
Ashley County Medical Center Installs Arkansas' First Fujifilm Aspire Cristalle With DBT
News | Mammography | August 27, 2019
Fujifilm Medical Systems U.S.A. Inc. recently announced that Ashley County Medical Center (Crossett, Ark.) has invested...
FDA Encourages Inclusion of Male Patients in Breast Cancer Clinical Trials
News | Women's Health | August 26, 2019
The U.S. Food and Drug Administration (FDA) released a new draft guidance that encourages including male patients in...
Moffitt Researchers Develop Model to Personalize Breast Cancer Radiation Treatment
News | Radiation Therapy | August 26, 2019
A personalized approach to cancer treatment has become more common over the last several decades, with numerous...
Sectra Signs Enterprise Imaging Contract With Vanderbilt Health
News | Enterprise Imaging | August 21, 2019
Sectra will install its enterprise imaging picture archiving and communication system (PACS) and vendor neutral archive...
Some Pregnant Women Are Exposed to Gadolinium in Early Pregnancy
News | Women's Health | August 20, 2019
A small but concerning number of women are exposed to a commonly used magnetic resonance imaging (MRI) contrast agent...
Lunit Receives Korea MFDS Approval for Lunit Insight MMG
News | Artificial Intelligence | August 19, 2019
Lunit has announced Korea Ministry of Food and Drug Safety (MFDS) approval of its artificial intelligence (AI) solution...
Imago Systems Announces Collaboration With Mayo Clinic for Breast Imaging

Image courtesy of Imago Systems

News | Mammography | August 14, 2019
Image visualization company Imago Systems announced it has signed a know-how license with Mayo Clinic. The multi-year...
Artificial Intelligence Could Yield More Accurate Breast Cancer Diagnoses
News | Artificial Intelligence | August 13, 2019
University of California Los Angeles (UCLA) researchers have developed an artificial intelligence (AI) system that...